China Resources Pharmaceutical Group Limited
CRPGF
$0.5414
$0.54140.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.29% | 7.14% | 1.32% | -0.22% | 12.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.29% | 7.14% | 1.32% | -0.22% | 12.13% |
| Cost of Revenue | 6.21% | 7.06% | 1.09% | -0.44% | 11.85% |
| Gross Profit | 6.74% | 7.59% | 2.51% | 0.96% | 13.72% |
| SG&A Expenses | 7.68% | 8.54% | -0.55% | -2.05% | 14.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -15.74% | -15.07% | 41.68% | 39.53% | 16.79% |
| Total Operating Expenses | 6.13% | 6.97% | 1.16% | -0.37% | 12.15% |
| Operating Income | 11.20% | 12.09% | 3.92% | 2.35% | 11.58% |
| Income Before Tax | 8.38% | 9.24% | 8.51% | 6.87% | 39.39% |
| Income Tax Expenses | 20.42% | 21.38% | 16.16% | 14.41% | 84.72% |
| Earnings from Continuing Operations | 4.64% | 5.48% | 6.60% | 4.99% | 29.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -35.04% | -36.12% | -21.01% | -19.18% | -22.71% |
| Net Income | -36.14% | -35.63% | -6.01% | -7.43% | 39.98% |
| EBIT | 11.20% | 12.09% | 3.92% | 2.35% | 11.58% |
| EBITDA | 8.83% | 9.70% | 4.01% | 2.44% | 20.14% |
| EPS Basic | -37.98% | -37.21% | -6.23% | -7.37% | 40.22% |
| Normalized Basic EPS | -30.15% | -30.15% | -9.09% | -10.56% | 86.30% |
| EPS Diluted | -37.01% | -36.22% | -7.21% | -8.33% | 38.04% |
| Normalized Diluted EPS | -30.15% | -30.15% | -9.09% | -10.56% | 86.30% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 1.66% | 1.66% | -- | -- | -0.24% |